Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models

Oncology Research

Volumn 12, Issue 11-12, 2000, Pages 501-508

  Luo, Xiang ^a   Li, Zujin ^a   Lin, Stanley ^a   Le, Trung ^a   Ittensohn, Martina ^a   Bermudes, David ^a   Runyab, Jacob D ^a   Shen, Shu Ying ^a   Chen, Jianping ^a   King, Ivan C ^a   Zheng, Li Mou ^a  

^a Vion Pharmaceuticals Incorporated   (United States)

Author keywords

Antitumor effect; Murine tumor model; Salmonella typhimurium; VNP20009

Indexed keywords

ANTINEOPLASTIC AGENT; LIVE VACCINE; VNP 20009;

ANIMAL; ARTICLE; COLON TUMOR; DOSE RESPONSE; EXPERIMENTAL MELANOMA; HUMAN; LUNG TUMOR; METASTASIS; MOUSE; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; SALMONELLA TYPHIMURIUM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; MICE, SCID; SALMONELLA TYPHIMURIUM; TRANSPLANTATION, HETEROLOGOUS; VACCINES, ATTENUATED;

EID: 0034585773     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747512     Document Type: Article

References (29)

1. Nauts, H.; Swift, W.; Coley, B. The treatment of malignant tumors by bacterial toxins as developed by the late William B Coley MD, reviewed in the light of modem research. Cancer Res. 6:205-216; 1946.
2. Gill, G.; Holden, A. A malignant pleural effusion infected with Salmonella enteritidis. Thorax 51:104-105; 1996.
3. Billings, P. C.; Uwaifo, A. O.; Heidelberger, C. Influence of benzoflavone on aflatoxin B1-induced cytotoxicity, mutation, and transformation of C3H/10TI/2 cells. Cancer Res. 43:2659-2663; 1983.
4. Giel, C. Abscess formation in a pheochromocytoma. N. Engl. J. Med. 251:980-982; 1954.
5. Grahwn, F.; Coleman, P. Infection of a secondary carcinoma by Salmonella Montevideo. Br. Med. J. 1:11-16; 1952.
6. Wolfe, J. A. Palaeobotanical evidence for a marked temperature increase following the cretaceous/tertiary boundary. Nature 343: 153-156; 1990.
7. Coley, W. The cancer symposium at Lake Mohonk. Am. J. Surg. 1:22-23; 1926.
8. Carey, R.; Holland, J.; Whang, H.; Neter, E.; Bryant, B. Clostridial oncolysis in man. Eur. J. Cancer 3:37-46; 1967.
9. Friberg, S. BCG in the treatment of superficial cancer of the bladder: A review. Med. Oncol. Tumor Pharmacother. 10:31-36; 1993.
10. Hoiseth, S. K.; Stocker, B. A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238-239; 1981.
11. O'Callaghan, D.; Maskell, D.; Liew, F. Y.; Easmon, C. F.; Dougan, G. Characterization of aromatic- and purine-dependent Salmonella typhimurium attenuation, persistence, and ability to induce protective immunity in Balb/c mice. Infect. Immun. 56:419-423; 1988.
12. Levin, M.; Herrington, D.; Murphy, J.; Morris, J.; Losonsky, G.; Tall, B.; Lindberg, A.; Svenson, S.; Baqar, S.; Edwards, M.; Stocker, B. Safety, infectivity, immumogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi. J. Clin. Invest. 79:888-902; 1987.
13. Strugnell, R. A.; Maskell, D.; Fairweather, N.; Pickard, D.; Cockayne, A.; Penn, C.; Dougan, G. Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene 88:57-63; 1990.
14. Eisenstein, T. K.; Bushnell, B.; Meissler, J. J., Jr.; Dalal, N.; Schafer, R.; Havas, H. F. Immunotherapy of a plasmacytoma with attenuated Salmonella. Med. Oncol. 12:103-108; 1995.
15. Pawelek, J. M.; Low, K. B.; Bermudes, D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537-4544; 1997.
16. Low, K. B.; Ittensohn, M.; Le, T.; Platt, J.; Sodi, S.; Amoss, M.; Ash, O.; Carmichael, E.; Chakraborty, A.; Fischer, J.; Lin, S. L.; Luo, X.; Miller, S. I.; Zheng, L.; King, I.; Pawelek, J. M.; Bermudes, D. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. 17:37-41; 1999.
17. Zheng, L. M.; Luo, X.; Feng, M.; Li, Z.; Le, T.; Ittensohn, M.; Trailsmith, M.; Bertnudes, D.; Lin, S. L.; King, I. C. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol. Res. 12:127-135; 2000.
18. Clairmont, C.; Lee, K. C.; Pike, J.; Ittensohn, M.; Low, K. B.; Pawelek, J.; Bermudes, D.; Brecher, S. M.; Margitich, D.; Turnier, J.; Li, Z.; Luo, X.; King, I.; Zheng, L. M. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J. Infect. Dis. 181:1996-2002; 2000.
19. Guilloteau, L. A.; Lax, A. J.; MacIntyre, S.; Wallis, T. S. The Salmonella dublin virulence plasmid does not modulate early T-cell responses in mice. Infect. Immun. 64:222-229; 1996.
20. Page-Clisson, M. E.; Pinto-Alphandary, H.; Chachaty, E.; Couvreur, P.; Andremont, A. Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharm. Res. 15:544-549; 1998.
21. Schafer, R.; Nacy, C. A.; Eisenstein, T. K. Induction of activated macrophages in C3H/HeJ mice by avirulent Salmonella. J. Immunol. 140:1638-1644; 1988.
22. Chen, J.; Sun, Y.; Nabel, G. J. Regulation of the proinflammatory effects of Fas ligand CD95L. Science 282:1714-1717; 1998.
23. Hardt, W.; Urlaub, H.; Galan, J. A substrate of the centisome 63 type III protein secretion system of Salmonella typhimurium is encoded by a cryptic bacteriophage. Proc. Natl. Acad. Sci. USA 95:2574-2579; 1998.
24. Lambin, P.; Nuyts, S.; Landuyt, W.; Theys, J.; De Bruijn, E.; Anne, J.; Van Mellaert, L.; Fowler, J. The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase. Int. J. Radiat. Biol. 76:285-293; 2000.
25. Thiele, E.; Arisen, R.; Boxer, G. Oncolysis by Clostridia IV. Effect of nonpathogenic clostridial spores in normal and pathological tissues. Cancer Res. 24:234-238; 1963.
26. Dang, L. H.; Bettegowda, C.; Huso, D. L.; Kinzler, K. W.; Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA 27:27; 2001.
27. Lee, K.; Zheng, L-M.; Luo, X.; Clairmont, C.; Fischer, J.; Margitich, D.; Tumier, J.; Almassian, B.; King, I Comparative toxicological evaluation in monkeys, pigs, and mice, of a genetically-engineered Salmonella VNP20009 being developed as an anti-tumor agent. Int. J. Toxicol. 19:19-25; 2000.
28. Izhar, M.; DeSilva, L.; Joysey, H. S.; Hormaeche, C. E. Moderate immunodeficiency does not increase susceptibility to Salmonella typhimurium aroA live vaccines in mice. Infect. Immun. 58:2258-2261; 1990.
29. Cunningham, C.; Nemunaitis, J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol No: CL-017. Version: April 9, 2001. Hum. Gene Ther. 12:1594-1596; 2001.